Skip to main content

Market Overview

Heat Biologics Rallies On Provisional Coronavirus Patent Application

Share:
Heat Biologics Rallies On Provisional Coronavirus Patent Application

Heat Biologics Inc (NASDAQ: HTBX) shares were trading more than 50% higher Monday after the Durham, North, Carolina-based biopharma company said in an SEC filing that it has filed a provisional patent application that would apply its immune system activating technology for the treatment or prevention of COVID-19, the new coronavirus originating from Wuhan, China. 

The company specializes in developing therapies to activate patients' immune systems against cancer. 

Heat Biologics' pipeline consists of three product candidates that are being tested as combination therapies for treating cancer.

Its pipeline is focused on T-cell activation and co-stimulation, as well as dual-acting immunotherapies to offer the potential benefits of combination immunotherapy without the need for multiple, independent biologics.

Its lead product candidate HS-110 is in Phase 2 development along with Bristol-Myers Squibb Co's (NYSE: BMY) Opdivo in non-small cell lung cancer.

Heat Biologics shares were spiking 59.15% higher to 53 cents at the time of publication. 

Related Links:

The Week Ahead In Biotech: COVID-19 Stocks In The Spotlight, Earnings Taper Off

GW Pharma's Epidiolex Label Expansion, EU Launch Key Growth Drivers In 2020

 

Related Articles (HTBX)

View Comments and Join the Discussion!

Posted-In: Coronavirus Covid-19 PatentsBiotech News Movers Trading Ideas General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com